Literature DB >> 16091250

Therapeutic drug monitoring: pharmacologic considerations for antiretroviral drugs.

Jennifer J Kiser1, Peter L Anderson, John G Gerber.   

Abstract

Therapeutic drug monitoring (TDM) is the process by which a patient's dosing regimen is guided by repeated measures of plasma drug concentrations. An enormous challenge with regard to TDM of antiretroviral drugs (ARV) is that the concentration goals can be moving targets. Well-designed prospective studies demonstrating that prospectively altering ARV doses based on TDM leads to virologic success and increased tolerability are needed. Nevertheless, there are specific clinical instances where this experimental intervention should be considered to potentially reduce toxicity and improve therapeutic outcomes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16091250     DOI: 10.1007/s11904-005-0020-8

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  31 in total

1.  Time to discontinuation of the first highly active antiretroviral therapy regimen: a comparison between protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-containing regimens.

Authors:  M Dorrucci; P Pezzotti; B Grisorio; C Minardi; M S Muro; V Vullo; A Monforte
Journal:  AIDS       Date:  2001-09-07       Impact factor: 4.177

Review 2.  Therapeutic drug monitoring in HIV infection: current status and future directions.

Authors:  David Back; Giorgio Gatti; Courtney Fletcher; Rodolphe Garaffo; Richard Haubrich; Richard Hoetelmans; Michael Kurowski; Andrew Luber; Concepta Merry; Carlo-Federico Perno
Journal:  AIDS       Date:  2002-03       Impact factor: 4.177

3.  Evaluation of antiretroviral drug measurements by an interlaboratory quality control program.

Authors:  Jacqueline A H Droste; Rob E Aarnoutse; Peter P Koopmans; Yechiel A Hekster; David M Burger
Journal:  J Acquir Immune Defic Syndr       Date:  2003-03-01       Impact factor: 3.731

4.  PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results.

Authors:  Philippe Clevenbergh; Rodolphe Garraffo; Jacques Durant; Pierre Dellamonica
Journal:  AIDS       Date:  2002-11-22       Impact factor: 4.177

Review 5.  Therapeutic drug monitoring in the treatment of HIV-infection.

Authors:  John G Gerber; Edward P Acosta
Journal:  J Clin Virol       Date:  2003-07       Impact factor: 3.168

6.  Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories.

Authors:  Diane T Holland; Robin DiFrancesco; Judith Stone; Fayez Hamzeh; James D Connor; Gene D Morse
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

Review 7.  Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors.

Authors:  P F Smith; R DiCenzo; G D Morse
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

8.  Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Authors:  C Marzolini; A Telenti; L A Decosterd; G Greub; J Biollaz; T Buclin
Journal:  AIDS       Date:  2001-01-05       Impact factor: 4.177

9.  Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients.

Authors:  J P Dieleman; I C Gyssens; M E van der Ende; S de Marie; D M Burger
Journal:  AIDS       Date:  1999-03-11       Impact factor: 4.177

10.  Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG).

Authors:  M A Chesney; J R Ickovics; D B Chambers; A L Gifford; J Neidig; B Zwickl; A W Wu
Journal:  AIDS Care       Date:  2000-06
View more
  1 in total

1.  Plasma concentrations of efavirenz and nevirapine among HIV-infected patients with immunological failure attending a tertiary hospital in North-western Tanzania.

Authors:  Daniel W Gunda; Christa Kasang; Benson R Kidenya; Rodrick Kabangila; Stephen E Mshana; Jeremiah Kidola; Samuel E Kalluvya; Gilbert W Kongola; Hartwig Klinker
Journal:  PLoS One       Date:  2013-09-10       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.